Brustin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brustin

The following information establishes the identity, composition, and general purpose of Brustin, strictly excluding details on dosages, specific clinical uses, side effects, or administration instructions.

Property Description
Active ingredient Acetaminophen and Ibuprofen
Form Oral tablet
Pharmacological class Combination Analgesic (with NSAID component)
Common use Relief of pain and fever
Origin Synthetic drug, Non-opioid

What Type of Medicine is Brustin?

Brustin is defined as a fixed-ratio combination product and is classified within the Combination Analgesic pharmacological group. It is supplied as an oral tablet and is typically categorized as an Over-the-counter (OTC) medication. This medicine is a synthetic drug, a feature common to its active components. As a defining characteristic, Brustin differs from single-ingredient pain relievers by integrating two established therapeutic agents, a strategy used for providing a broader spectrum of action in managing discomfort.

What are the Active Ingredients in Brustin?

The core composition of Brustin features the two non-opioid active substances: Acetaminophen (Paracetamol) and Ibuprofen. Ibuprofen belongs to the class of Non-steroidal Anti-inflammatory Drugs (NSAIDs), whereas Acetaminophen functions as a central-acting analgesic and antipyretic. These agents are combined for pain management. This specific fixed-dose combination is a synergistic formulation, designed to integrate the distinct actions of both ingredients to achieve relief.

What is the General Purpose of This Combination Analgesic?

The primary therapeutic purpose of this combination analgesic is to offer relief from various forms of pain and to reduce fever. A typical neutral use scenario for Brustin is the temporary relief of general body aches. The inclusion of the NSAID component, Ibuprofen, contributes an anti-inflammatory effect that targets the source of pain peripherally, while Acetaminophen reinforces the pain and fever relief through central action. Ibuprofen and Acetaminophen are ingredients used for temporary relief. This dual-action mechanism is why the fixed-ratio combination product is a tool for addressing symptoms involving both pain and elevated body temperature.

Regulatory References

  1. Acetaminophen
  2. Ibuprofen
  3. Combination Analgesic
  4. NSAID component
  5. pain
  6. fever
  7. non-opioid
  8. anti-inflammatory effect

What side effects are possible with Brustin?

Possible Side Effects and Safety Information

The safety profile of Brustin is based on data derived from regulatory documents, detailing its officially documented adverse reactions and safety considerations.

Adverse Reactions

Adverse reactions are classified by frequency and system organ class. The most frequently reported adverse reactions are related to Gastrointestinal Disorders (e.g., Nausea and Vomiting, which are Very Common especially during treatment initiation) and a Flu-like Syndrome, which is also very common and tends to decrease with continued therapy.

Frequency Category Key Adverse Reactions
Very Common Nausea, Vomiting, Flu-like Syndrome
Common Pulmonary Embolism, Thrombocytopenia, Hypertension, Tumour Haemorrhage, Febrile Neutropenia
Uncommon Severe Cerebral Oedema, Hypermethioninemia
Rare Interstitial Pneumonia, Pulmonary Oedema, Pulmonary Infiltrates, Adult Respiratory Distress Syndrome (ARDS)

Serious and Clinically Significant Safety Concerns

The most important serious adverse reactions include Pulmonary Embolism, Thrombocytopenia, Tumour Haemorrhage, and Febrile Neutropenia. There is a documented risk of rare but potentially fatal pulmonary undesirable effects, including Interstitial Pneumonia and ARDS. Patients with a recent history of pulmonary infiltrates or pneumonia may be at a higher risk for these events.

Uncommon cases of Severe Cerebral Oedema and Hypermethioninemia have been reported, typically occurring within two weeks to six months after therapy initiation. Close safety monitoring, as defined in official regulatory labels, is applied to address these identified risks, particularly ARDS and interstitial pneumonia.

Overdose and Emergency Response

Overdose involving this combination analgesic is associated with the distinct toxicological profiles of its two active ingredients. The acetaminophen component carries a risk of severe, potentially fatal hepatic necrosis (liver failure), while the ibuprofen component may lead to acute renal failure, gastrointestinal bleeding, seizures, or cardiovascular collapse.

Early clinical signs of overdose may include nausea, vomiting, diaphoresis, and malaise. Symptoms of liver damage, such as jaundice (yellowing of the skin or eyes), may be delayed for 24 hours or longer, meaning an individual may appear well immediately following exposure. Ibuprofen overdose manifestations typically include abdominal pain, drowsiness, lethargy, and signs of metabolic acidosis.

Due to the risk of delayed, severe toxicity, regulatory guidance mandates that immediate medical attention must be sought for any confirmed or suspected overdose, regardless of the presence or absence of symptoms.

Management of this overdose profile involves time-critical procedures. A specific antidote (N-acetylcysteine) is available for the acetaminophen component and must be administered promptly. No specific antidote is known for the ibuprofen component, which is managed primarily with symptomatic and supportive treatment. Hospital monitoring and repeated plasma concentration measurements are required to assess toxicity levels and guide care, particularly in patients with pre-existing hepatic impairment.

Therapeutic Uses of Brustin

What Brustin Treats: Main Uses and Benefits

Brustin, an analgesic combining Ibuprofen and Acetaminophen, is applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort and systemic imbalance. The fixed-dose combination is used for managing symptoms that interfere with daily comfort.


Managing Acute Pain, Inflammation, and Discomfort

This medicine is relevant in contexts marked by increased discomfort or tension, generally helping with symptoms related to physical discomfort such as headache, toothache, backache, and muscular aches. It is also applied in addressing symptoms linked to inflammatory or irritative states, including minor pain of arthritis and menstrual cramps. It contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities.

Support for Systemic Illness and Elevated Body Temperature

Brustin is applicable within circumstances that involve acute or disruptive symptom patterns, particularly when patients experience symptoms related to systemic imbalance, such as fever and generalized body aches associated with the common cold. It is used for managing elevated body temperature (fever). It supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Mild to Moderate Pain and Fever

Regulatory References

  1. U.S. National Library of Medicine (NIH MedlinePlus overview)

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Brustin — Official Regulatory Information

The official eligibility for the Acetaminophen/Ibuprofen combination product, Brustin, is defined by absolute regulatory restrictions and cautionary conditions related to its two active components.

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents starting from 12 years of age [3.1, 3.4].
Populations for whom use is contraindicated Patients with known hypersensitivity to Ibuprofen, Acetaminophen, aspirin, or other NSAIDs [1.1, 2.5]. Patients with a history of recurrent gastrointestinal ulceration or hemorrhage [1.1]. Patients with severe hepatic failure, severe renal failure, or severe heart failure [2.7]. Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery [1.1].
Age-related eligibility rules Minimum age for standard use is 12 years; use in children younger than 12 years is not established [3.1, 3.4]. Older adults should use with caution due to increased risk of adverse reactions [1.1].
Pregnancy and lactation eligibility status Contraindicated in the third trimester of pregnancy [1.1, 2.5]. Use after 20 weeks of pregnancy is discouraged due to potential fetal harm [2.5]. Use during lactation is generally not recommended [1.1].

These official eligibility statements strictly determine who can and cannot use the drug. Absolute non-eligibility (contraindications) is mandated for individuals with severe organ failure (heart, liver, kidney), GI bleeding history, or specific NSAID allergies, applying the most restrictive rules from both active ingredients. Populations with less severe organ impairment or certain cardiovascular risk factors are advised to use the medicine only with caution, as explicitly stated in the product labeling [1.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Brustin’s interaction profile is primarily structured around avoiding additive toxicity and managing pharmacokinetic and pharmacodynamic interference, as defined in official regulatory documents.

Interaction Scope

Category Constraint or Official Effect
Contraindicated Combinations Co-administration with any other drug containing Acetaminophen or any other NSAID is formally prohibited. The medicine is contraindicated for pain relief during perioperative coronary artery bypass graft (CABG) surgery.
Pharmacokinetic Interactions Co-administration with CYP2C9 Inhibitors (e.g., Fluconazole) results in an officially documented increase of Ibuprofen plasma exposure (Cmax and AUC).
Pharmacodynamic Interactions Co-administration with Anticoagulants (e.g., Warfarin) increases the documented risk of serious bleeding. The drug reduces renal elimination of Lithium, leading to an increased plasma concentration. Diuretics and ACE Inhibitors/ARBs have reduced efficacy and an increased risk of renal impairment when co-administered.
Substance Interactions Concurrent use with alcohol increases the documented risk of both severe liver damage and gastrointestinal bleeding.
Timing-Separation Rules For low-dose Aspirin (le 81 mg/ day), the Ibuprofen component must be administered at least 8 hours before or 30 minutes after immediate-release Aspirin to avoid blunting the antiplatelet effect.

Interaction-Context Constraints

This structure dictates strict avoidance of specific combinations and mandatory caution for agents with documented changes in plasma levels. Regulatory documents caution that elderly patients have an officially heightened susceptibility to NSAID-induced renal impairment when co-administered with diuretics or ACE inhibitors.

Mechanism of Action

Dual-Site Inhibition of Prostaglandin Synthesis

Brustin operates by inhibiting Cyclooxygenase (COX) enzymes, the catalysts for producing Prostaglandins ( PGE2), which are key mediators in physiological response. This mechanism is dual-acting: Ibuprofen provides non-selective COX inhibition in peripheral tissues to limit local inflammatory mediator signaling, while Acetaminophen selectively inhibits COX activity within the Central Nervous System (CNS) to adjust the central processing of these signals.

Central Modulation of Pain and Temperature

The central component, Acetaminophen, engages mechanisms within the hypothalamus and spinal cord. By limiting PGE2 synthesis in these central areas, the drug modulates the elevated thermal set-point. Furthermore, this CNS action contributes to elevating the body’s pain threshold, thereby modulating central nociceptive signal processing.

Mechanistic Synergy and Complementarity

The core physiological effect stems from the complementary action of the two ingredients. Ibuprofen influences the peripheral generation of nociceptive signals via a mechanism that attenuates inflammation, while Acetaminophen influences the central processing of these signals. This integration of peripheral attenuation and central dampening provides combined physiological modulation across both anatomical compartments.

Dosage and Administration Information

How to Use Brustin: General Administration Guidelines

The administration of Brustin, an oral fixed-dose combination of Ibuprofen (125 mg) and Acetaminophen (250 mg) per tablet, is based on a regimen for use. The medicine is intended for oral intake, administered as a unit dose tablet.

Standard Dosage and Frequency

The standard single dose is 2 tablets, which delivers Ibuprofen 250 mg and Acetaminophen 500 mg. This regimen is applied to adults and children 12 years of age and older. Dosing is typically spaced with a minimum interval of 8 hours between administrations. The maximum daily administration does not exceed 6 tablets in any 24-hour period, which limits the total daily dose to 750 mg of Ibuprofen and 1500 mg of Acetaminophen.

Administration Conditions and Constraints

The overall use pattern for Brustin is defined as short-term or temporary relief. For self-treatment, administration should not extend beyond 10 days. The medicine may be taken with food or milk if the individual experiences stomach discomfort upon administration. It is important to note that Brustin is not used concurrently with any other prescription or nonprescription product containing Acetaminophen or any other Non-steroidal Anti-inflammatory Drug (NSAID). For children younger than 12 years of age, a healthcare provider should be consulted for guidance on use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Brustin

The research on the fixed-dose combination of Acetaminophen and Ibuprofen (Brustin) focuses on describing its performance compared to its individual components and a placebo, primarily in short-term pain models. The goal of this overview is to describe what the studies have explored and what the findings report so far, according to authoritative sources.


Evidence for Use in Acute Pain Models

Research into the effects of this combination has mainly been conducted using Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms that occur following a known procedure, such as the surgical removal of wisdom teeth (a standardized model for acute pain). Outcomes measured included patient-reported outcomes describing perceived discomfort and the time it took for patients to feel a change in their symptoms. Findings describe patterns observed in the studies, examining variables such as pain relief scores, compared to placebo or the individual active agents.


Evidence for Use in General Pain and Fever

Research also examined the combination for conditions characterized by fluctuating or episodic manifestations, such as general body aches, headache, and menstrual cramps. For the reduction of elevated body temperature, studies monitored outcomes related to physiological strain or stress, such as the reduction and duration of elevated body temperature. What is known about this medicine's use for general aches and fever is often contextualized by the well-documented effects of both Acetaminophen and Ibuprofen, which are separately recognized by regulatory bodies for use in conditions involving pain and fever.


What Remains Uncertain and Research Gaps

The comparative evidence is lacking for showing consistent outcomes of the combination over its individual components across all types of mild-to-moderate acute pain. Additionally, subgroup findings are uncertain, as sample sizes were modest in non-standardized populations. The research evidence for the combination is largely drawn from studies using a single standardized pain model, meaning the results apply only to the populations studied under those conditions. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes that would describe the sustained or repeated use of the combination beyond the short duration consistent with temporary symptom relief.

Key Studies & References

  1. Acetaminophen; Ibuprofen (Oral Route) - NIH DailyMed Consumer Drug Information

Frequently Asked Questions (FAQ)

Common questions about Brustin (FAQ)

Q: What makes Brustin different from other similar treatments?

Official product information describes Brustin as a fixed-dose combination of Ibuprofen and Acetaminophen. This is notable because the two active components work in complementary ways: Ibuprofen acts peripherally to help limit inflammation, while Acetaminophen acts centrally to modulate pain and fever signals. This allows the medication to address pain through two different mechanisms.

Q: Does Brustin need to be taken at a specific time of day?

Regulatory guidance defines the use pattern based on time intervals, requiring a minimum of 8 hours between each dose. There is no instruction in the official label that specifies the drug must be taken at a particular time of day, such as morning or night.

Q: Where can I find the official prescribing information for Brustin?

The comprehensive, official information for this medicine can be found in the product's official drug label or Product Monograph. These authoritative documents are published and maintained by government regulatory bodies, such as the FDA or EMA, for each authorized product.

Q: What happens when Brustin is combined with herbal supplements?

The official product information does not list every possible herbal supplement interaction. However, some supplements may impact liver function or blood clotting, which can interfere with the components of Brustin. Regulatory guidance emphasizes the importance of disclosing all supplements and medications to a healthcare professional.

Q: What are the main contraindications listed for Brustin?

According to regulatory documents, the medicine is contraindicated (should not be used) in certain situations. These include known allergies to the active ingredients or other NSAIDs, active peptic ulcer or internal bleeding, severe heart or liver disease, and for pain relief during coronary artery bypass graft (CABG) surgery.

Q: What is Brustin generally prescribed for?

Official regulatory indications state that Brustin is used for the temporary relief of minor aches and pains. This includes common issues like headache, backache, toothache, and menstrual cramps, in addition to being used for the reduction of fever.

Q: How quickly does a person typically start feeling the effects of Brustin?

Official product information relates the drug's action to the absorption characteristics of its ingredients. While the exact time can vary among individuals, the drug's formulation is related to the characteristics of its ingredients, which suggests an expectation of effect following administration.

Q: What happens if I miss taking a dose of Brustin?

Official guidance outlines a protocol for a missed dose that involves maintaining the required time interval before the next scheduled dose. This protocol defines when to take a delayed dose versus skipping it entirely to prevent administration exceeding regulatory limits.

Q: Is it common to feel fatigued while taking Brustin?

Official product safety information indicates that fatigue, dizziness, and drowsiness are among the commonly reported side effects. Patients should be aware of these potential effects when using the medication.

Q: What are the most commonly reported side effects of Brustin?

Regulatory safety summaries list several common side effects. These frequently include gastrointestinal symptoms like upset stomach, nausea, and vomiting, along with headache, dizziness, and drowsiness.

Q: How long does it take for Brustin to be completely out of the system?

The drug's clearance time is related to the half-life of its components, which informs the minimum 8-hour interval required between doses. The exact time the medicine takes to leave the body entirely is a pharmacokinetic detail not typically detailed in general patient materials.

Q: Is Brustin safe for use in older adults?

Regulatory documents note that specific problems limiting the drug's effectiveness have not been demonstrated in older adults. However, because this population may have an increased risk of specific adverse effects, such as cardiovascular or kidney issues, official documentation details that professional consideration is necessary.

Q: Can women who are planning pregnancy use Brustin?

Official prescribing information indicates that the medicine is strictly contraindicated during the third trimester of pregnancy due to documented risks to the fetus. Use during the first and second trimesters is subject to professional guidance due to documented risks.

Q: Is it normal to have mild headaches when first starting Brustin?

Official safety summaries list headache as a commonly reported side effect. Symptoms that persist or worsen are generally subject to professional evaluation.

Q: Is Brustin addictive or habit-forming?

According to official drug classification and regulatory documents, the active ingredients, Ibuprofen and Acetaminophen, are not classified as controlled substances and are not generally considered addictive or habit-forming.

Q: Is there a risk of weight gain while on Brustin?

Weight gain is not listed as a common side effect in the product's official safety summaries. The Ibuprofen component has been rarely associated with fluid retention or edema, which can sometimes result in temporary changes in body weight.

Q: Does Brustin cause drowsiness or affect driving ability?

Official safety information notes that dizziness and drowsiness are documented as potential side effects of this medication. The product label notes the potential for functional impairment, which may affect the ability to drive or operate machinery.

Q: What should I do if a side effect seems concerning but not severe?

Regulatory guidance describes a procedure for reporting side effects that are concerning or persistent to a healthcare professional for evaluation.

Q: Are there specific symptoms that mean I should stop taking Brustin?

The official label documents critical symptoms (e.g., signs of gastrointestinal bleeding or severe allergic reactions) that necessitate immediate cessation of the drug and emergency professional intervention.

Q: Can Brustin be split or crushed to make it easier to swallow?

The regulatory status of whether a tablet can be split or crushed depends on its specific formulation. Official sources emphasize the importance of maintaining dose integrity and may note that liquid forms or professional consultation are available options when swallowing tablets is difficult.

Q: What is the difference between the active and inactive ingredients in Brustin?

The active components, Ibuprofen and Acetaminophen, are the substances responsible for the medication's therapeutic effect. In contrast, the inactive ingredients, known as excipients, are added to aid in the tablet's formulation, stability, appearance, and proper absorption in the body.

Q: Can Brustin affect birth control pills?

The official interaction profile does not typically list specific hormonal birth control medications as a major interaction. The official documentation emphasizes the importance of disclosing all medications to a healthcare provider to assess potential interference.

Q: Is sun exposure a concern while taking Brustin?

Rare instances of photosensitivity, which is an increased sensitivity to the sun, have been reported with the Ibuprofen component of this medicine. Official safety information notes this documented risk and describes measures to avoid or minimize direct sun exposure.

Q: How long after stopping Brustin can I safely take other medicines?

The required 'washout' time before starting a new medicine depends entirely on the specific medication being introduced. The determination of a safe interval for introducing another medication must be made by a healthcare professional.

Q: Is it safe to get vaccinated while taking Brustin?

Official regulatory documents generally do not list specific interactions with common vaccinations. However, some healthcare providers may suggest temporarily avoiding pain relievers around the time of a vaccination to ensure a full immune response or to clearly track potential side effects.

Q: Can taking Brustin cause mood changes?

The official safety documents list mental or mood changes as a potential serious side effect that necessitates monitoring and reporting to a healthcare professional.

Q: Does Brustin have a Black Box Warning?

As a fixed-dose combination containing an NSAID and Acetaminophen, the medicine carries mandatory Boxed Warnings concerning serious risks. These warnings address the documented increased risk of cardiovascular events, such as heart attack and stroke, and serious gastrointestinal adverse events, such as bleeding and ulcers.

Q: What happens if a child accidentally takes Brustin?

Official regulatory guidance stresses that accidental ingestion or overdose by a child is a medical emergency. This guidance requires prompt professional intervention by contacting a Poison Control Center or emergency services.

Q: Do I need special monitoring while using Brustin?

For the typical short-term duration of use, no specialized monitoring is usually required. However, for patients using the medication long-term under professional guidance, regulatory documents advise that periodic blood and urine tests may be necessary to check for potential effects on kidney and liver function.

Q: Is it possible for Brustin to cause allergic reactions?

Yes, official warnings confirm that severe allergic reactions are a documented risk with this medicine, particularly in patients with a known allergy to aspirin or other NSAIDs. The documented symptoms of a severe reaction, such as hives or swelling of the face, are those that necessitate prompt professional medical intervention.

How should Brustin be stored and disposed of?

The storage and disposal of Brustin (Acetaminophen/Ibuprofen oral tablets) must adhere strictly to officially documented regulatory requirements to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Prohibitions Keep the medicine from freezing and avoid excessive heat above 40 C.
Protection Must be stored in a closed container and protected away from heat, moisture, and direct light.
Child Safety Mandatory instruction to keep the product out of the sight and reach of children.

Disposal Instructions

Do not keep medicine that is outdated or no longer needed. The preferred regulatory method for disposing of unused tablets is through an official drug take-back program. If a take-back option is unavailable, the medicine must be mixed with an unappealing substance and placed in a sealed container before disposal in the household trash. The tablets must not be flushed down a toilet or thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brustin found in:

A-Z Index: